By Daniella Parra
Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.
Sequana is working to relieve patients of this burden with alfapump which automatically removes ascitic fluid from the abdomen into the bladder for natural elimination through urination, freeing patients of repeated and invasive drainage procedures, they said.
“The alfapump represents a significant advancement for our patients suffering from recurrent ascites,” Dr. Rahul Patel, Assistant Professor of Radiology and Surgery at Icahn School of Medicine, said. “For too long, these patients have had to put up with repeated needle punctures, burdensome procedures to drain the ascites fluid. With the alfapump system, patients have this done automatically and continuously, avoiding the punctures and the hospital visits, and maintaining a flat abdomen. This groundbreaking technology offers our patients the potential for improved quality of life and reduced hospital visits, which is truly transformative for managing this challenging condition.”
READ MORE
NYSE Firesides Scheduled Dec 9, 2025 & Feb 3, 2026
Never Miss our Weekly Highlights HERE
Contact:
Exec Edge
Editor@executives-edge.com
Click HERE to follow us on LinkedIn
